Search

Your search keyword '"Bhavani, Perumal Kannabiran"' showing total 2 results
Start Over Author "Bhavani, Perumal Kannabiran" Publisher escholarship, university of california
2 results on '"Bhavani, Perumal Kannabiran"'

1. Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV‐Coinfected Children in India: Recommendations for Dose Modifications

Author

Guiastrennec, Benjamin, Ramachandran, Geetha, Karlsson, Mats O, Kumar, AK Hemanth, Bhavani, Perumal Kannabiran, Gangadevi, N Poorana, Swaminathan, Soumya, Gupta, Amita, Dooley, Kelly E, and Savic, Radojka M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Pediatric, Rare Diseases, Infectious Diseases, Orphan Drug, Prevention, HIV/AIDS, Tuberculosis, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Age Factors, Antitubercular Agents, Body Weight, Child, Child, Preschool, Coinfection, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Dosage Calculations, Drug Monitoring, Drug Therapy, Combination, Female, HIV Infections, Humans, India, Infant, Isoniazid, Male, Models, Biological, Pyrazinamide, Rifampin, Time Factors, Treatment Outcome, Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences
Abstract

This work aimed to evaluate the once-daily antituberculosis treatment as recommended by the new Indian pediatric guidelines. Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines. The exposure-response relationships were established using a population pharmacokinetic-pharmacodynamic approach. Rifampin exposure was identified as the unique predictor of treatment outcome. Consequently, children with low body weight (4-7 kg) and/or HIV infection, who displayed the lowest rifampin exposure, were associated with the highest probability of unfavorable treatment (therapy failure, death) outcome (Punfavorable ). Model-based simulation of optimized (Punfavorable ≤ 5%) rifampin once-daily doses were suggested per treatment weight band and HIV coinfection status (33% and 190% dose increase, respectively, from the new Indian guidelines). The established dose-exposure-response relationship could be pivotal in the development of future pediatric tuberculosis treatment guidelines.

Published
2018

2. Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.

Author

Guiastrennec, Benjamin, Ramachandran, Geetha, Karlsson, Mats O, Kumar, AK Hemanth, Bhavani, Perumal Kannabiran, Gangadevi, N Poorana, Swaminathan, Soumya, Gupta, Amita, Dooley, Kelly E, and Savic, Radojka M

Subjects
Humans, Tuberculosis, HIV Infections, Body Weight, Isoniazid, Pyrazinamide, Rifampin, Antitubercular Agents, Drug Monitoring, Treatment Outcome, Drug Therapy, Combination, Drug Administration Schedule, Age Factors, Dose-Response Relationship, Drug, Models, Biological, Time Factors, Adolescent, Child, Child, Preschool, Infant, India, Female, Male, Drug Dosage Calculations, Coinfection, Drug Therapy, Combination, Dose-Response Relationship, Drug, Models, Biological, Preschool, Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy
Abstract

This work aimed to evaluate the once-daily antituberculosis treatment as recommended by the new Indian pediatric guidelines. Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines. The exposure-response relationships were established using a population pharmacokinetic-pharmacodynamic approach. Rifampin exposure was identified as the unique predictor of treatment outcome. Consequently, children with low body weight (4-7 kg) and/or HIV infection, who displayed the lowest rifampin exposure, were associated with the highest probability of unfavorable treatment (therapy failure, death) outcome (Punfavorable ). Model-based simulation of optimized (Punfavorable ≤ 5%) rifampin once-daily doses were suggested per treatment weight band and HIV coinfection status (33% and 190% dose increase, respectively, from the new Indian guidelines). The established dose-exposure-response relationship could be pivotal in the development of future pediatric tuberculosis treatment guidelines.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results